His 2015 employment agreement, for instance, stipulated 2.25 million share grants if Valeant achieved 50% compound annual returns over five years, or a stock price of $1,068 by 2020. Large incentives create a focus on profitability, but Valeant's current troubles also show how they can go too far. On Wednesday, Pearson, former CFO Schiller, and top investor Bill Ackman of Pershing Square testified in front of a Senate committee that accused the company of acquiring monopoly positions in a number of drugs, allowing it to use price increases to gouge consumers and insurers. All three indicated the company went too far in its aggressiveness. Valeant is now working to prove it can live without the acquisitions and drug price increases that ginned up its shares.